Pleryon Therapeutics Receives Approval from Health Canada to undertake a first-in-human clinical trial for its Lubricin-inspired Polymer P002 in Dry Eye Disease at CORE, University of Waterloo
Pleryon Therapeutics Completes 35M RMB Series A Financing to Accelerate Clinical Development of Innovative Therapies for Osteoarthritis and Dry Eye Disease